When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Paying for gifts, decorations and gingerbread houses can become quite expensive, so the U.S. Department of the Interior is hoping to ease some financial burden by making Christmas trees more ...

Steve Ottman was born to sell Christmas trees. Ottman, 73, said his family has been growing the holiday staple in Wisconsin since the Great Depression. But now his 50-acre Christmas tree farm just ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Estrella Luna-Diez receives funding from UK Research & Innovation (UKRI) and the Natural Environment Research Council (NERC). Anne-Marie Culhane receives funding from UKRI and the NERC. Bruno Barcante ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Management reaffirmed guidance for 2025 on an expense base of less than $450 million, "excluding all of the partnership inflows." For 2026, guidance was also reaffirmed at less than $390 million.